ReviewJournal of translational medicine2025
m5C RNA modification in colorectal cancer: mechanisms and therapeutic targets.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- RNA-Binding Peptide Influences Epitranscriptomic Regulation by Preferentially Binding to Unmodified RNAs Targeted by NSUN2.Biomolecules · 2026Article
- Nanocarriers engineering for efficient NSUN2 silencing and immune responsive therapy in metastatic colorectal cancer.Materials today. Bio · 2026Article
- 5-Methylcytidine RNA Epitranscriptomics in Women's Health and Disease: Mechanisms and Clinical Implications.Cells · 2026Review
- Role and clinical importance of lactylation in tumors (Review).Molecular medicine reports · 2026Review
- Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances.Molecular biomedicine · 2026Review
- Advances in research on RNA methylation and its role in the immune microenvironment of gastrointestinal tumors.Frontiers in cell and developmental biology · 2026Review
- Marked for Success: How RNA mCellular and molecular gastroenterology and hepatology · 2026Review
- RNA epitranscriptomic regulation of tumor immune evasion: mechanisms, context-dependent roles, and therapeutic implications.Frontiers in immunology · 2026Review
- m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis.International journal of genomics · 2026Article
- Targeting the NSUN2-DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer.Frontiers in pharmacology · 2026Article
- Engineered Protein Modification: A New Paradigm for Enhancing Biosensing Sensitivity and Diagnostic Accuracy.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-Methylcytosine (m5C), an important RNA modification, has been extensively studied in colorectal cancer (CRC). In recent years, with advances in high-throughput sequencing technology and RNA modification detection tools, the role of m5C modification in tumorigenesis and development has been gradually elucidated and regulated by "writers," "erasers," and "readers," m5C modification affects many biological processes and cancer progression, including cell proliferation, autophagy, invasion, and apoptosis. In CRC, m5C modification affects cancer cell proliferation, migration, invasion, drug resistance, and immunotherapy resistance by regulating RNA stability, metabolic reprogramming, signalling pathway activation, and immune escape. Moreover, m5C modification provides potential biomarkers and targets for early diagnosis and efficacy prediction. In addition, studies on drugs that target m5C modification related proteins have shown that intervention in m5C modification may provide new directions for immunotherapy and molecular therapy for patients with CRC. In summary, m5C modification, an important epigenetic regulators in CRC, provides a new perspective on the mechanism underlying cancer therapy and precision medicine research. Future research should focus on revealing the specific role of m5C modification in the tumor microenvironment and drug resistance mechanisms and promote its clinical translation in diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.